Oral Pleuromutilins BC-3205 & BC-3781

The pleuromutilins BC-3205 & BC-3781 belong to the first generation of pleuromutilins to combine excellent oral bioavailability with substantial activity against gram-positive pathogens and atypicals as well as some gram-negative pathogens. 
In particular, both drug candidates are highly active against multi-drug resistant (MDR) pathogens including methicillin resistant Staphylococcus aureus (MRSA), MDR Streptococcus pneumonia (i.e. macrolide and quinolone resistance), and vancomycin resistant Enterococcus faecium. They are characterized by excellent in vivo activities (e.g. pneumonia model), outstanding PK/PD parameters, allowing once a day dosing, and a novel mode of action.

Regulatory Stage

Nabriva’s two systemic products, BC-3205 and BC-3781, are being developed for both oral and IV administration with extensive phase I data becoming available during 2009. Both are intended for the treatment of  serious multi-drug resistant skin & skin structure infections (CSSI) and moderate to severe pneumonia (CAP, HAP etc).

Topical Pleuromutilin BC-7013

Nabriva owns a comprehensive topical program with the pleuromutilin BC-7013 being the most advanced drug candidate. BC-7013 belongs to a subclass of pleuromutilins which are characterized by outstanding activities against resistant gram-positive pathogens, in particular MRSA, and perfect PK/PD parameters in skin. Its properties qualify BC-7013 for the topical treatment of a number of bacterial associated or derived dermatological diseases.

Regulatory Stage

BC-7013 is currently undergoing Phase I clinical trials.